Pharmorubicin
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors (NCT05920863) | Zhejiang Cancer Hospital | 2023-07-01 |
Track Pharmorubicin automatically
Every clearance here is in the API, with alerts when new ones post.